Skip to main content
SpringerLink
Log in

ASH 2022—new developments in acute myeloid leukemia

  • review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Recent years have provided progress for the treatment of acute myeloid leukemia (AML) patients by translating insights from basic research on AML biology into new drugs and concepts. The latest developments presented at the 2022 annual meeting of the American Society of Hematology (ASH) are covered in this review, including discussion of new classifications, treatment of elderly unfit patients, and new approaches towards allogeneic transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–19.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28.

    Article  CAS  PubMed  Google Scholar 

  3. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77.

    Article  PubMed  Google Scholar 

  4. Huber S, Baer C, Hutter S, et al. AML and MDS classification according to who 2022 and international consensus classification: do we invent a babylonian confusion of languages? Blood. 2022;140(Supplement 1):555–6.

    Article  Google Scholar 

  5. Song GY, Kim T, Ahn SY, et al. Prognostic predictability of 2022 European Leukemianet (ELN) risk stratification in the real world. Blood. 2022;140(Supplement 1):1018–9.

    Article  Google Scholar 

  6. Döhner H, Pratz KW, DiNardo CD, et al. ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with Venetoclax and Azacitidine. Blood. 2022;140(Supplement 1):1441–4.

    Article  Google Scholar 

  7. Hernández Sánchez A, Ramiro AV, Strang E, et al. Machine learning allows the identification of new co-mutational patterns with prognostic implications in NPM1 mutated AML—results of the European Harmony Alliance. Blood. 2022;140(Supplement 1):739–42.

    Article  Google Scholar 

  8. Pratz KW, Jonas BA, Pullarkat VA, et al. Long-term follow-up of the phase 3 Viale—a clinical trial of Venetoclax plus Azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Blood. 2022;140(Supplement 1):529–31.

    Article  Google Scholar 

  9. Willekens C, Chraibi S, Decroocq J, et al. Reduced Venetoclax exposition to seven days of Azacitidine is efficient in treatment-naïve patients with acute myeloid leukemia. Blood. 2022;140(Supplement 1):537–8.

    Article  Google Scholar 

  10. Reville PK, Kantarjian H, Borthakur G, et al. Venetoclax added to Cladribine (CLAD) + low dose AraC (LDAC) alternating with Azacitidine (AZA) is highly active as frontline therapy in older patients with newly diagnosed acute Myeloid leukemia in a phase 2 study. Blood. 2022;140(Supplement 1):9041–3.

    Article  Google Scholar 

  11. Chua CC, Loo S, Reynolds J, et al. High response and prolonged treatment-free remission after a short-course of modified intensive chemotherapy and Venetoclax in elderly AML: an updated analysis of the caveat trial. Blood. 2022;140(Supplement 1):1708–10.

    Article  Google Scholar 

  12. Desikan SP, Konopleva M, Takahashi K, et al. Updated phase IIb results of Venetoclax with FLAG-IDA in relapsed or refractory acute myeloid leukemia. Blood. 2022;140(Supplement 1):534–6.

    Article  Google Scholar 

  13. Daver N, Senapati J, Maiti A, et al. Phase I/II study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older/unfit or high-risk acute Myeloid leukemia (AML) and relapsed/refractory (R/R) AML. Blood. 2022;140(Supplement 1):141–4.

    Article  Google Scholar 

  14. Daver N, Montesinos P, Aribi A, et al. Abstr 62 broad activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax triplet in high-risk patients with relapsed/refractory acute Myeloid leukemia (AML). Blood. 2022;140(Supplement 1):145–9.

    Article  Google Scholar 

  15. Short N, DiNardo CD, Daver N, et al. Updated results from a phase I/II study of the triplet combination of Azacitidine, Venetoclax and Gilteritinib for patients with FLT3-mutated acute Myeloid leukemia. Blood. 2022;140(Supplement 1):2007–9.

    Article  Google Scholar 

  16. Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845–57.

    Article  CAS  PubMed  Google Scholar 

  17. Daver N, Perl AE, Maly J, et al. Venetoclax plus Gilteritinib for FLT3-mutated relapsed/refractory acute Myeloid leukemia. J Clin Oncol. 2022;40(35):4048–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Janssen M, Schmidt C, Bruch PM, et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL‑1. Blood. 2022;140(24):2594–610.

    Article  CAS  PubMed  Google Scholar 

  19. Stelljes M, Middeke JM, Bug G, et al. In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by Allo-HCT: results from the randomized phase III ASAP trial. Blood. 2022;140(Supplement 1):9–11.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Third Medical Department, Hanusch Hospital, H. Collinstr. 30, 1140, Vienna, Austria

    Michael Pfeilstöcker

Authors
  1. Michael Pfeilstöcker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Pfeilstöcker.

Ethics declarations

Conflict of interest

M. Pfeilstöcker: honoraria as speaker and/or consultant: Abbvie, BMS, Jazz, Novartis, Sandoz, Sobi, financial support for scientific projects: BMS.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pfeilstöcker, M. ASH 2022—new developments in acute myeloid leukemia. memo 16, 156–159 (2023). https://doi.org/10.1007/s12254-023-00896-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-023-00896-z

Keywords

Search

Navigation